DIKUL - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources UL. For full access, REGISTER.

2 3 4 5 6
hits: 101
31.
  • OP19 Gaps between ECCO qual... OP19 Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey
    Fidalgo, C; Walsh, A; Adamina, M ... Journal of Crohn's and colitis, 01/2023, Volume: 17, Issue: Supplement_1
    Journal Article
    Peer reviewed

    Abstract Background Recently, the European Crohn’s and Colitis Organisation (ECCO) Consensus on Quality-of-Care (QoC) Standards proposed essential criteria on the structure of units who manage ...
Full text
Available for: UL
32.
  • Bioaccumulation in Porcelli... Bioaccumulation in Porcellio scaber (Crustacea, Isopoda) as a measure of the EDTA remediation efficiency of metal-polluted soil
    Udovic, Metka; Drobne, Damjana; Lestan, Domen Environmental pollution (1987), 10/2009, Volume: 157, Issue: 10
    Journal Article
    Peer reviewed

    Leaching using EDTA applied to a Pb, Zn and Cd polluted soil significantly reduced soil metal concentrations and the pool of metals in labile soil fractions. Metal mobility (Toxicity Characteristic ...
Full text
Available for: UL
33.
  • P589 A population pharmacok... P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis
    Kantasiripitak, W; Dreesen, E; Detrez, I ... Journal of Crohn's and colitis, 01/2019, Volume: 13, Issue: Supplement_1
    Journal Article
    Peer reviewed
    Open access

    Abstract Background From the PURSUIT programme, it is known that golimumab (GLM) trough concentrations (TC) >2.5 mg/l at week (w)6 of induction therapy are associated with clinical response in ...
Full text
Available for: UL

PDF
34.
  • P180 Association between se... P180 Association between serum and tissue protein profiles in patients with active inflammatory bowel disease: the ASCERTAIN study
    Stevens, T; Wildenberg, M; Koželj, M ... Journal of Crohn's and colitis, 01/2020, Volume: 14, Issue: Supplement_1
    Journal Article
    Peer reviewed
    Open access

    Abstract Background To facilitate personalised treatment of inflammatory bowel disease (IBD), biomarkers for disease entity and disease severity in easily accessible samples are required. Therefore, ...
Full text
Available for: UL

PDF
35.
  • P674 Ustekinumab is the pre... P674 Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort
    Verstockt, B; Vieujean, S; Truyens, M ... Journal of Crohn's and colitis, 01/2023, Volume: 17, Issue: Supplement_1
    Journal Article
    Peer reviewed
    Open access

    Abstract Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory disease affecting skin that bears apocrine glands and is characterised by painful, deep-seated, inflamed ...
Full text
Available for: UL
36.
  • The Toxicity of Zinc to Ter... The Toxicity of Zinc to Terrestrial Isopods in a "Standard" Laboratory Test
    Drobne, D.; Hopkin, S.P. Ecotoxicology and environmental safety, 06/1995, Volume: 31, Issue: 1
    Journal Article
    Peer reviewed

    A method is described for assessing the effects of metals on the food consumption rate of isopods from measurements of fecal production. The effects of zinc in the diets of two isopod species, ...
Full text
Available for: UL
37.
  • Effects of magnetic cobalt ... Effects of magnetic cobalt ferrite nanoparticles on biological and artificial lipid membranes
    Drašler, Barbara; Drobne, Damjana; Novak, Sara ... International journal of nanomedicine, 01/2014, Volume: 9, Issue: Issue 1
    Journal Article
    Peer reviewed
    Open access

    The purpose of this work is to provide experimental evidence on the interactions of suspended nanoparticles with artificial or biological membranes and to assess the possibility of suspended ...
Full text
Available for: UL

PDF
38.
  • N17 Frequency of infliximab... N17 Frequency of infliximab-induced skin lesions and their impact on quality of life in inflammatory bowel disease patients treated with infliximab
    Bobnar Sekulic, C; Polanc, T; Koren, U ... Journal of Crohn's and colitis, 01/2019, Volume: 13, Issue: Supplement_1
    Journal Article
    Peer reviewed
    Open access

    Abstract Background IBD patients treated with infliximab (IFX) develop drug-induced skin lesions in 20–30%. The impact of IFX-induced skin lesions on quality of life (QoL) is unknown. Methods In this ...
Full text
Available for: UL

PDF
39.
  • P686 Neither high inflixima... P686 Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study
    Kurent, T; Koren, U; Hanzel, J ... Journal of Crohn's and colitis, 01/2019, Volume: 13, Issue: Supplement_1
    Journal Article
    Peer reviewed

    Abstract Background Skin lesions induced by infliximab are an important side effect and lead to drug discontinuation in many cases. It is not known whether these lesions occur more often with ...
Full text
Available for: UL
40.
Full text
Available for: UL
2 3 4 5 6
hits: 101

Load filters